Image1_TRAIL-R1-Targeted CAR-T Cells Exhibit Dual Antitumor Efficacy.jpg
Tumor necrosis factor–related apoptosis-inducing ligand receptor 1 (TRAIL-R1) has limited expression in normal tissues but was highly expressed in various types of tumors, making it an attractive target for cancer immunotherapy. Here, we utilized the single-chain variable fragment (scFv) from our previously identified TRAIL-R1–targeting monoclonal antibody (TR1419) with antitumor efficacy and produced the TR1419 chimeric antigen receptor (CAR) T cells. We characterized the phenotypes and functions of these CAR-T cells and found that the third-generation TR1419-28BBζ CAR-T cells exhibited greater target sensitivity and proliferative capability, with slightly higher PD-1 expression after antigen stimulation. Importantly, we found that the TR1419 CAR-T cells could induce TRAIL-R1–positive tumor cell death via a dual mechanism of the death receptor–dependent apoptosis as well as the T-cell–mediated cytotoxicity. Altogether, the TR1419 CAR-T cells could serve as a promising strategy for targeting the TRAIL-R1–positive tumors.
History
References
- https://doi.org//10.3390/cancers11091228
- https://doi.org//10.1172/jci.insight.126194
- https://doi.org//10.1016/j.ccell.2019.01.002
- https://doi.org//10.18632/oncotarget.14285
- https://doi.org//10.1038/onc.2011.315
- https://doi.org//10.1016/j.ymthe.2018.07.005
- https://doi.org//10.1073/pnas.86.24.10024
- https://doi.org//10.1172/jci.insight.96976
- https://doi.org//10.1038/s41467-020-18925-4
- https://doi.org//10.1016/j.bbrc.2016.05.089
- https://doi.org//10.1084/jem.20021196
- https://doi.org//10.1007/s40259-015-0122-9
- https://doi.org//10.1186/1471-2407-14-30
- https://doi.org//10.1016/0092-8674(91)90314-o
- https://doi.org//10.1002/eji.201040551
- https://doi.org//10.1038/nm.1966
- https://doi.org//10.1016/0959-8049(96)00015-9
- https://doi.org//10.1126/science.aar6711
- https://doi.org//10.1200/jco.2014.56.2025
- https://doi.org//10.1016/S0140-6736(14)61403-3
- https://doi.org//10.3389/fonc.2020.01067
- https://doi.org//10.7150/thno.19893
- https://doi.org//10.1038/s41419-020-02941-9
- https://doi.org//10.1038/nbt.4195
- https://doi.org//10.1126/scisignal.aap9777
- https://doi.org//10.3390/genes11060703
- https://doi.org//10.3389/fimmu.2019.02514
- https://doi.org//10.1172/JCI46110
- https://doi.org//10.1016/s0014-5793(97)01231-3
- https://doi.org//10.1080/19420862.2016.1172163
- https://doi.org//10.1016/j.vaccine.2011.11.058
- https://doi.org//10.3390/cells8050472
- https://doi.org//10.1016/j.ccell.2019.12.014
- https://doi.org//10.1182/blood.2020005278
- https://doi.org//10.1038/s41467-020-18444-2
- https://doi.org//10.1172/JCI85309
- https://doi.org//10.1186/1471-2407-14-74
- https://doi.org//10.1186/s12967-019-02206-w
- https://doi.org//10.1073/pnas.1016388108
- https://doi.org//10.3892/etm.2019.7491
- https://doi.org//10.2217/imt.15.129
CC BY 4.0